References
Key articles
National Institutes of Health; National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma. Aug 2007 [internet publication].Full text
Global Initiative for Asthma. 2024 global strategy for asthma management and prevention. May 2024 [internet publication].Full text
Parsons JP, Hallstrand TS, Mastronarde JG, et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 2013 May 1;187(9):1016-27.Full text Abstract
Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC); Cloutier MM, Baptist AP, Blake KV, et al. 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020 Dec;146(6):1217-70.Full text Abstract
Reference articles
1. National Institutes of Health; National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma. Aug 2007 [internet publication].Full text
2. Weiler JM, Brannan JD, Randolph CC, et al. Exercise-induced bronchoconstriction update: 2016. J Allergy Clin Immunol. 2016 Nov;138(5):1292-5.Full text Abstract
3. Global Initiative for Asthma. 2024 global strategy for asthma management and prevention. May 2024 [internet publication].Full text
4. Lai K, Satia I, Song WJ, et al. Cough and cough hypersensitivity as treatable traits of asthma. Lancet Respir Med. 2023 Jul;11(7):650-62. Abstract
5. GBD 2019 Chronic Respiratory Diseases Collaborators. Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019. EClinicalMedicine. 2023 May;59:101936.Full text Abstract
6. Global Asthma Network. The global asthma report 2022 [internet publication].Full text
7. Centers for Disease Control and Prevention. Asthma Data: most recent national asthma data. Nov 2024 [internet publication].Full text
8. Chowdhury NU, Guntur VP, Newcomb DC, et al. Sex and gender in asthma. Eur Respir Rev. 2021 Nov 17;30(162):210067.Full text Abstract
9. Centers for Disease Control and prevention. Asthma: most recent national asthma data. May 2023 [internet publication].Full text
10. Centers for Disease Control and Prevention. Asthma as the underlying cause of death. Jul 2023 [internet publication].Full text
11. Grandinetti R, Fainardi V, Caffarelli C, et al. Risk factors affecting development and persistence of preschool wheeezing: consensus document of the Emilia-Romagna Asthma (ERA) study group. J Clin Med. 2022 Nov 4;11(21):6558.Full text Abstract
12. Ruan Z, Shi Z, Zhang G, et al. Asthma susceptible genes in children: a meta-analysis. Medicine (Baltimore). 2020 Nov 6;99(45):e23051.Full text Abstract
13. Cardenas A, Fadadu RP, Koppelman GH. Epigenome-wide association studies of allergic disease and the environment. J Allergy Clin Immunol. 2023 Sep;152(3):582-90.Full text Abstract
14. Ntontsi P, Photiades A, Zervas E, et al. Genetics and epigenetics in asthma. Int J Mol Sci. 2021 Feb 27;22(5):2412.Full text Abstract
15. Aarafi H, Yadegari A, Dastgheib SA, et al. Association of +1923C > T, -1112C > T and +2044A > G polymorphisms in IL-13 gene with susceptibility to pediatric asthma: a systematic review and meta-analysis. Fetal Pediatr Pathol. 2022 Apr;41(2):259-77. Abstract
16. Fan Z, Liu T, Na W. Association of nitric oxide synthase gene polymorphism with asthma: a systematic review and meta-analysis. Clin Respir J. 2023 Jun;17(6):516-26.Full text Abstract
17. Chen X, Hu J, Li K, et al. Association of the IL-4R Q576R polymorphism with pediatric asthma: a meta-analysis. Afr Health Sci. 2022 Sep;22(3):307-16.Full text Abstract
18. Kang SW, Kim SK, Han YR, et al. Promoter polymorphism (-308G/A) of tumor necrosis factor-alpha (TNF-α) gene and asthma risk: an updated meta-analysis. Genet Test Mol Biomarkers. 2019 Jun;23(6):363-72. Abstract
19. Yu X, Wang LW, He Q, et al. Correlation study on β2-adrenergic receptor gene polymorphisms and asthma susceptibility: evidence based on 57 case-control studies. Eur Rev Med Pharmacol Sci. 2019 May;23(9):3908-25.Full text Abstract
20. He L, Zhou X, Mo H, et al. The association between vitamin D receptor gene polymorphisms and asthma: a systematic review and meta-analysis. Ann Palliat Med. 2022 Feb;11(2):574-87.Full text Abstract
21. Restori KH, Srinivasa BT, Ward BJ, et al. Neonatal immunity, respiratory virus infections, and the development of asthma. Front Immunol. 2018;9:1249.Full text Abstract
22. Singh AM, Busse WW. Asthma exacerbations. 2: aetiology. Thorax. 2006 Sep;61(9):809-16.Full text Abstract
23. Bobolea I, Hagemann J, Sanak M, et al. Current goals of NSAID-ERD management: patient-centered approaches involving NSAID desensitization with and without biologics. J Allergy Clin Immunol Pract. 2024 Nov;12(11):2934-44.Full text Abstract
24. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J. 2000 Sep;16(3):432-6.Full text Abstract
25. Morales DR, Guthrie B, Lipworth BJ, et al. NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity. Allergy. 2015 Jul;70(7):828-35. Abstract
26. Pietinalho A, Pelkonen A, Rytilä P. Linkage between smoking and asthma. Allergy. 2009 Dec;64(12):1722-7.Full text Abstract
27. Ferreira MA, Vonk JM, Baurecht H, et al. Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. Nat Genet. 2017 Dec;49(12):1752-57. Abstract
28. Joshi D, Duong M, Kirkland S, et al. Impact of electronic cigarette ever use on lung function in adults aged 45-85: a cross-sectional analysis from the Canadian Longitudinal Study on Aging. BMJ Open. 2021 Oct 27;11(10):e051519.Full text Abstract
29. Wills TA, Soneji SS, Choi K, et al. E-cigarette use and respiratory disorders: an integrative review of converging evidence from epidemiological and laboratory studies. Eur Respir J. 2021 Jan;57(1):1901815.Full text Abstract
30. Rose JJ, Krishnan-Sarin S, Exil VJ, et al. Cardiopulmonary impact of electronic cigarettes and vaping products: a scientific statement from the American Heart Association. Circulation. 2023 Aug 22;148(8):703-28. Abstract
31. Boogaard H, Patton AP, Atkinson RW, et al. Long-term exposure to traffic-related air pollution and selected health outcomes: A systematic review and meta-analysis. Environ Int. 2022 Jun;164:107262.Full text Abstract
32. Brunekreef B, Strak M, Chen J, et al. Mortality and morbidity effects of long-term exposure to low-level PM(2.5), BC, NO(2), and O(3): an analysis of European cohorts in the ELAPSE project. Res Rep Health Eff Inst. 2021 Sep;2021(208):1-127.Full text Abstract
33. Orellano P, Quaranta N, Reynoso J, et al. Effect of outdoor air pollution on asthma exacerbations in children and adults: systematic review and multilevel meta-analysis. PLoS One. 2017 Mar 20;12(3):e0174050.Full text Abstract
34. Paterson CA, Sharpe RA, Taylor T, et al. Indoor PM2.5, VOCs and asthma outcomes: a systematic review in adults and their home environments. Environ Res. 2021 Nov;202:111631.Full text Abstract
35. Nassikas NJ, McCormack MC, Ewart G, et al. Indoor air sources of outdoor air pollution: health consequences, policy, and recommendations: an official American Thoracic Society workshop report. Ann Am Thorac Soc. 2024 Mar;21(3):365-76.Full text Abstract
36. Maung TZ, Bishop JE, Holt E, et al. Indoor air pollution and the health of vulnerable groups: a systematic review focused on particulate matter (PM), volatile organic compounds (VOCs) and their effects on children and people with pre-existing lung disease. Int J Environ Res Public Health. 2022 Jul 19;19(14):8752.Full text Abstract
37. Liu N, Bu Z, Liu W, et al. Health effects of exposure to indoor volatile organic compounds from 1980 to 2017: a systematic review and meta-analysis. Indoor Air. 2022 May;32(5):e13038. Abstract
38. Sharma V, Cowan DC. Obesity, inflammation, and severe asthma: an update. Curr Allergy Asthma Rep. 2021 Dec 18;21(12):46.Full text Abstract
39. Miethe S, Karsonova A, Karaulov A, et al. Obesity and asthma. J Allergy Clin Immunol. 2020 Oct;146(4):685-93.Full text Abstract
40. Xie L, Chandrasekhar A, DeSantis SM, et al. Discontinuation and reduction of asthma medications after metabolic and bariatric surgery: a systematic review and meta-analysis. Obes Rev. 2023 Feb;24(2):e13527. Abstract
41. Oosterholt S, Pavord ID, Brusselle G, et al. Modelling ASthma TrEatment Responses (MASTER): effect of individual patient characteristics on the risk of exacerbation in moderate or severe asthma: a time-to-event analysis of randomized clinical trials. Br J Clin Pharmacol. 2023 Nov;89(11):3273-90.Full text Abstract
42. Thompson CA, Eslick SR, Berthon BS, et al. Asthma medication use in obese and healthy weight asthma: systematic review/meta-analysis. Eur Respir J. 2021 Mar;57(3):2000612.Full text Abstract
43. Scott HA, Ng SH, McLoughlin RF, et al. Effect of obesity on airway and systemic inflammation in adults with asthma: a systematic review and meta-analysis. Thorax. 2023 Oct;78(10):957-65. Abstract
44. Burbank AJ, Hernandez ML, Jefferson A, et al. Environmental justice and allergic disease: a work group report of the AAAAI Environmental Exposure and Respiratory Health Committee and the Diversity, Equity and Inclusion Committee. J Allergy Clin Immunol. 2023 Mar;151(3):656-70.Full text Abstract
45. van der Wiel E, ten Hacken NH, Postma DS, et al. Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review. J Allergy Clin Immunol. 2013 Mar;131(3):646-57. Abstract
46. Saikumar Jayalatha AK, Hesse L, Ketelaar ME, et al. The central role of IL-33/IL-1RL1 pathway in asthma: from pathogenesis to intervention. Pharmacol Ther. 2021 Sep;225:107847.Full text Abstract
47. Han YY, Zhang X, Wang J, et al. Multidimensional assessment of asthma identifies clinically relevant phenotype overlap: a cross-sectional study. J Allergy Clin Immunol Pract. 2021 Jan;9(1):349-62.e18. Abstract
48. Luo W, Hu J, Xu W, et al. Distinct spatial and temporal roles for Th1, Th2, and Th17 cells in asthma. Front Immunol. 2022;13:974066.Full text Abstract
49. Yue M, Gaietto K, Han YY, et al. Transcriptomic profiles in nasal epithelium and asthma endotypes in Youth. JAMA. 2025 Jan 28;333(4):307-18.Full text Abstract
50. Seys SF, Long MB. The quest for biomarkers in asthma: challenging the T2 versus non-T2 paradigm. Eur Respir J. 2022 Feb 17;59(2):2102669.Full text Abstract
51. Ballow M. Biologic immune modifiers: trials and tribulations - are we there yet? J Allergy Clin Immunol. 2006 Dec;118(6):1209-15. Abstract
52. Wark PA, Gibson PG. Asthma exacerbations. 3: pathogenesis. Thorax. 2006 Oct;61(10):909-15.Full text Abstract
53. Boyce JA. Asthma 2005-2006: bench to bedside. J Allergy Clin Immunol. 2006 Sep;118(3):582-6. Abstract
54. Cockcroft DW, Davis BE. Mechanisms of airway hyperresponsiveness. J Allergy Clin Immunol. 2006 Sep;118(3):551-9. Abstract
55. Kuruvilla ME, Vanijcharoenkarn K, Shih JA, et al. Epidemiology and risk factors for asthma. Respir Med. 2019 Mar;149:16-22.Full text
56. Koefoed HJL, Zwitserloot AM, Vonk JM, et al. Asthma, bronchial hyperresponsiveness, allergy and lung function development until early adulthood: a systematic literature review. Pediatr Allergy Immunol. 2021 Aug;32(6):1238-54.Full text Abstract
57. Boogaard H, Patton AP, Atkinson RW, et al. Long-term exposure to traffic-related air pollution and selected health outcomes: a systematic review and meta-analysis. Environ Int. 2022 Jun;164:107262.Full text Abstract
58. Huang J, Yang X, Fan F, et al. Outdoor air pollution and the risk of asthma exacerbations in single lag0 and lag1 exposure patterns: a systematic review and meta-analysis. J Asthma. 2022 Nov;59(11):2322-39.Full text Abstract
59. Ravnborg N, Ambikaibalan D, Agnihotri G, et al. Prevalence of asthma in patients with atopic dermatitis: a systematic review and meta-analysis. J Am Acad Dermatol. 2021 Feb;84(2):471-8. Abstract
60. Gabryszewski SJ, Hill DA. One march, many paths: insights into allergic march trajectories. Ann Allergy Asthma Immunol. 2021 Sep;127(3):293-300. Abstract
61. Wu T, Jahangir MR, Mensink-Bout SM, et al. Visceral adiposity and respiratory outcomes in children and adults: a systematic review. Int J Obes (Lond). 2022 Jun;46(6):1083-100.Full text Abstract
62. Zhu Z, Guo Y, Shi H, et al. Shared genetic and experimental links between obesity-related traits and asthma subtypes in UK Biobank. J Allergy Clin Immunol. 2020 Feb;145(2):537-49.Full text Abstract
63. Shore SA. Obesity and asthma: possible mechanisms. J Allergy Clin Immunol. 2008 May;121(5):1087-93. Abstract
64. King GG, Brown NJ, Diba C, et al. The effects of body weight on airway calibre. Eur Respir J. 2005 May;25(5):896-901.Full text Abstract
65. Polosa R, Thomson NC. Smoking and asthma: dangerous liaisons. Eur Respir J. 2013 Mar;41(3):716-26.Full text Abstract
66. Jonas A. Impact of vaping on respiratory health. BMJ. 2022 Jul 18;378:e065997. Abstract
67. Bradford LE, Rebuli ME, Ring BJ, et al. Danger in the vapor? ECMO for adolescents with status asthmaticus after vaping. J Asthma. 2020 Nov;57(11):1168-72. Abstract
68. Wold LE, Tarran R, Crotty Alexander LE, et al. Cardiopulmonary consequences of vaping in adolescents: a scientific statement from the American Heart Association. Circ Res. 2022 Jul 22;131(3):e70-82.Full text Abstract
69. Tackett AP, Urman R, Barrington-Trimis J, et al. Prospective study of e-cigarette use and respiratory symptoms in adolescents and young adults. Thorax. 2024 Jan 18;79(2):163-8.Full text Abstract
70. Pérez A, Valencia S, Jani PP, et al. Use of electronic nicotine delivery systems and age of asthma onset among US adults and youths. JAMA Netw Open. 2024 May 1;7(5):e2410740.Full text Abstract
71. Heikkilä P, Korppi M, Ruotsalainen M, et al. Viral wheezing in early childhood as a risk factor for asthma in young adulthood: a prospective long-term cohort study. Health Sci Rep. 2022 Mar;5(2):e538.Full text Abstract
72. Feddema JJ, Claassen E. Prevalence of viral respiratory infections amongst asthmatics: results of a meta-regression analysis. Respir Med. 2020 Nov;173:106020.Full text Abstract
73. Laidlaw TM, Mullol J, Woessner KM, et al. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1133-41.Full text Abstract
74. Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45-53.Full text Abstract
75. Redmond C, Akinoso-Imran AQ, Heaney LG, et al. Socioeconomic disparities in asthma health care utilization, exacerbations, and mortality: a systematic review and meta-analysis. J Allergy Clin Immunol. 2022 May;149(5):1617-27.Full text Abstract
76. Paoletti G, Melone G, Ferri S, et al. Gastroesophageal reflux and asthma: when, how, and why. Curr Opin Allergy Clin Immunol. 2021 Feb 1;21(1):52-58. Abstract
77. Cantarutti A, Barbiellini Amidei C, Valsecchi C, et al. Association of treated and untreated gastroesophageal reflux disease in the first year of life with the subsequent development of asthma. Int J Environ Res Public Health. 2021 Sep 13;18(18):9633. Abstract
78. Rogers L. Role of sleep apnea and gastroesophageal reflux in aevere asthma. Immunol Allergy Clin North Am. 2016 Aug;36(3):461-71. Abstract
79. Kopsaftis Z, Yap HS, Tin KS, et al. Pharmacological and surgical interventions for the treatment of gastro-oesophageal reflux in adults and children with asthma. Cochrane Database Syst Rev. 2021 May 17;5:CD001496.Full text Abstract
80. Zheng Z, Luo Y, Li J, et al. Randomised trials of proton pump inhibitors for gastro-oesophageal reflux disease in patients with asthma: an updated systematic review and meta-analysis. BMJ Open. 2021 Aug 10;11(8):e043860.Full text Abstract
81. Prasad B, Nyenhuis SM, Imayama I, et al. Asthma and abstructive sleep apnea overlap: what has the evidence taught us? Am J Respir Crit Care Med. 2020 Jun 1;201(11):1345-57.Full text Abstract
82. Kong DL, Qin Z, Shen H, et al. Association of obstructive sleep apnea with asthma: a meta-analysis. Sci Rep. 2017 Jun 22;7(1):4088.Full text Abstract
83. Toelle BG, Xuan W, Peat JK, et al. Childhood factors that predict asthma in young adulthood. Eur Respir J. 2004 Jan;23(1):66-70.Full text Abstract
84. Crump C, Sundquist J, Sundquist K. Preterm or early term birth and long-term risk of asthma into midadulthood: a national cohort and cosibling study. Thorax. 2023 Jul;78(7):653-60.Full text Abstract
85. Pulakka A, Risnes K, Metsälä J, et al. Preterm birth and asthma and COPD in adulthood: a nationwide register study from two Nordic countries. Eur Respir J. 2023 Jun 22;61(6):2201763.Full text Abstract
86. Htet TD, Teede HJ, de Courten B, et al. Asthma in reproductive-aged women with polycystic ovary syndrome and association with obesity. Eur Respir J. 2017 May 1;49(5):1601334.Full text Abstract
87. Sun H, Li D, Jiao J, et al. A potential link between polycystic ovary syndrome and asthma: a meta-analysis. Reprod Sci. 2022 Jan;29(1):312-9. Abstract
88. Xu Y, Zhou ZY, Pan JX, et al. Associations between asthma and polycystic ovary syndrome: current perspectives. Front Endocrinol (Lausanne). 2022;13:936948.Full text Abstract
89. Juber NF, Abdulle A, AlJunaibi A, et al. Association between pediatric asthma and adult polycystic ovarian syndrome (PCOS): a cross-sectional analysis of the UAE healthy future Study (UAEHFS). Front Endocrinol (Lausanne). 2023;14:1022272.Full text Abstract
90. Cassim R, Russell MA, Lodge CJ, et al. The role of circulating 25 hydroxyvitamin D in asthma: a systematic review. Allergy. 2015 Apr;70(4):339-54.Full text Abstract
91. Williamson A, Martineau AR, Sheikh A, et al. Vitamin D for the management of asthma. Cochrane Database Syst Rev. 2023 Feb 6;2(2):CD011511.Full text Abstract
92. Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta-analysis of individual participant data. Lancet Respir Med. 2017 Nov;5(11):881-90.Full text Abstract
93. Wang Y, Wang J, Chen L, et al. Efficacy of vitamin D supplementation on COPD and asthma control: a systematic review and meta-analysis. J Glob Health. 2022 Dec 16;12:04100.Full text Abstract
94. El Abd A, Dasari H, Dodin P, et al. The effects of vitamin D supplementation on inflammatory biomarkers in patients with asthma: a systematic review and meta-analysis of randomized controlled trials. Front Immunol. 2024;15:1335968.Full text Abstract
95. Mocelin HT, Fischer GB, Bush A. Adverse early-life environmental exposures and their repercussions on adult respiratory health. J Pediatr (Rio J). 2022 Mar-Apr;98 Suppl 1(suppl 1):S86-S95.Full text Abstract
96. Litonjua AA, Carey VJ, Laranjo N, et al. Six-year follow-up of a trial of antenatal vitamin D for asthma reduction. N Engl J Med. 2020 Feb 6;382(6):525-33.Full text Abstract
97. Gupta S, Thériault G. Do not diagnose or routinely treat asthma or chronic obstructive pulmonary disease without pulmonary function testing. BMJ. 2023 Mar 20;380:e072834.
98. Louis R, Satia I, Ojanguren I, et al. European Respiratory Society guidelines for the diagnosis of asthma in adults. Eur Respir J. 2022 Feb 15;2101585 [Epub ahead of print].Full text Abstract
99. Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022 Jul 13;60(1):2101499.Full text Abstract
100. Parsons JP, Hallstrand TS, Mastronarde JG, et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 2013 May 1;187(9):1016-27.Full text Abstract
101. British Thoracic Society. BTS clinical statement: assessment and management of respiratory problems in athletic individuals. Apr 2022 [internet publication].Full text
102. Cockcroft DD. Direct and indirect challenges in the clinical assessment of asthma. Ann Allergy Asthma Immunol. 2009 Nov;103(5):363-9. Abstract
103. Lee J, Song JU. Diagnostic comparison of methacholine and mannitol bronchial challenge tests for identifying bronchial hyperresponsiveness in asthma: a systematic review and meta-analysis. J Asthma. 2021 Jul;58(7):883-91.Full text Abstract
104. Guida G, Bagnasco D, Carriero V, et al. Critical evaluation of asthma biomarkers in clinical practice. Front Med (Lausanne). 2022;9:969243.Full text Abstract
105. Agache I, Akdis CA, Akdis M, et al. EAACI biologicals guidelines: recommendations for severe asthma. Allergy. 2021 Jan;76(1):14-44.Full text Abstract
106. Oppenheimer J, Hoyte FCL, Phipatanakul W, et al. Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions. Ann Allergy Asthma Immunol. 2022 Aug;129(2):169-80.Full text Abstract
107. Guida G, Bertolini F, Carriero V, et al. Reliability of total serum IgE levels to define type 2 high and low asthma phenotypes. J Clin Med. 2023 Aug 22;12(17):5447.Full text Abstract
108. Wang E, Wechsler ME. A rational approach to compare and select biologic therapeutics in asthma. Ann Allergy Asthma Immunol. 2022 Apr;128(4):379-89.Full text Abstract
109. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021 Jul;9(7):2680-8.e7.Full text Abstract
110. Menzies-Gow A, Mansur AH, Brightling CE. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020 Mar;55(3):1901633.Full text Abstract
111. Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC); Cloutier MM, Baptist AP, Blake KV, et al. 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020 Dec;146(6):1217-70.Full text Abstract
112. Khatri SB, Iaccarino JM, Barochia A, et al. Use of fractional exhaled nitric oxide to guide the treatment of asthma: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2021 Nov 15;204(10):e97-109.Full text Abstract
113. Alahmadi F, Peel A, Keevil B, et al. Assessment of adherence to corticosteroids in asthma by drug monitoring or fractional exhaled nitric oxide: a literature review. Clin Exp Allergy. 2021 Jan;51(1):49-62.Full text Abstract
114. Korevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. Lancet Respir Med. 2015 Apr;3(4):290-300. Abstract
115. Petsky HL, Kew KM, Turner C, et al. Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database Syst Rev. 2016 Sep 1;(9):CD011440.Full text Abstract
116. Petsky HL, Li A, Chang AB. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev. 2017 Aug 24;(8):CD005603.Full text Abstract
117. Benson VS, Hartl S, Barnes N, et al. Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis. Eur Respir J. 2022 Jan 13;59(1):2004590.Full text Abstract
118. Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet. 2011 Sep 10;378(9795):983-90. Abstract
119. Honkoop PJ, Loijmans RJ, Termeer EH, et al; Asthma Control Cost-Utility Randomized Trial Evaluation (ACCURATE) Study Group. Symptom-and fraction of exhaled nitric oxide-driven strategies for asthma control: a cluster-randomized trial in primary care. J Allergy Clin Immunol. 2015 Mar;135(3):682-8. Abstract
120. American College of Radiology. ACR appropriateness criteria: adult. Chronic dyspnea. Unclear etiology. Initial imaging. 2024 [internet publication].Full text
121. Castagnoli R, Licari A, Brambilla I, et al. An update on the role of chronic rhinosinusitis with nasal polyps as a co-morbidity in severe asthma. Expert Rev Respir Med. 2020 Dec;14(12):1197-205.Full text Abstract
122. Mullol J, Maldonado M, Castillo JA, et al. Management of united airway disease focused on patients with asthma and chronic rhinosinusitis with nasal polyps: a systematic review. J Allergy Clin Immunol Pract. 2022 Sep;10(9):2438-47.e9. Abstract
123. Backer V, Cardell LO, Lehtimäki L, et al. Multidisciplinary approaches to identifying and managing global airways disease: expert recommendations based on qualitative discussions. Front Allergy. 2023;4:1052386. Abstract
124. Pollart SM, Compton RM, Elward KS. Management of acute asthma exacerbations. Am Fam Physician. 2011 Jul 1;84(1):40-7.Full text Abstract
125. National Institute for Health and Care Excellence. Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN). Nov 2024 [internet publication].Full text
126. Vandenplas O, Suojalehto H, Cullinan P. Diagnosing occupational asthma. Clin Exp Allergy. 2017 Jan;47(1):6-18.Full text Abstract
127. Asamoah-Boaheng M, Farrell J, Osei Bonsu K, et al. Examining risk factors accelerating time-to-chronic obstructive pulmonary disease (COPD) diagnosis among asthma patients. COPD. 2022;19(1):47-56.Full text Abstract
128. U.S. Food and Drug Administration. Drug safety communication: FDA requires boxed warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. March 2020 [internet publication].Full text
129. Lan G, Huang C, Liu Y, et al. How does comorbid bronchiectasis affect asthmatic patients? A meta-analysis. J Asthma. 2021 Oct;58(10):1314-28. Abstract
130. Carden KA, Boiselle PM, Waltz DA, et al. Tracheomalacia and tracheobronchomalacia in children and adults. An in-depth review. Chest. 2005 Mar;127(3):984-1005.Full text Abstract
131. Lee KS, Sun MRM, Ernst A, et al. Comparison of dynamic expiratory CT with bronchoscopy for diagnosing airway malacia: a pilot evaluation. Chest. 2007 Mar;131(3):758-64.Full text Abstract
132. Mohan A, Lugogo NL, Hanania NA, et al. Questions in mild asthma: an official American Thoracic Society research statement. Am J Respir Crit Care Med. 2023 Jun 1;207(11):e77-96. Abstract
133. Canadian Thoracic Society. Canadian Thoracic Society 2021 guideline update: diagnosis and management of asthma in preschoolers, children and adults. Aug 2021 [internet publication].Full text
134. Canadian Thoracic Society. Recognition and management of severe asthma: a Canadian Thoracic Society position statement. 2017 [internet publication].Full text
135. Global Initiative for Asthma. Diagnosis and management of difficult-to-treat & severe asthma. 2023 [internet publication].Full text
136. Al-Moamary MS, Alhaider SA, Allehebi R, et al. The Saudi initiative for asthma - 2024 update: guidelines for the diagnosis and management of asthma in adults and children. Ann Thorac Med. 2024 Jan-Mar;19(1):1-55.Full text Abstract
137. Niimi A, Fukunaga K, Taniguchi M, et al. Executive summary: Japanese guidelines for adult asthma (JGL) 2021. Allergol Int. 2023 Apr;72(2):207-26.Full text Abstract
138. Kawamatawong T, Sangasapaviriya A, Saiphoklang N, et al. Guidelines for the management of asthma in adults: evidence and recommendations. Asian Pac J Allergy Immunol. 2022 Mar;40(1):1-21.Full text Abstract
139. National Asthma Council. Australian asthma handbook: the national guidelines for health professionals. April 2022 [internet publication].Full text
140. National Institute for Health and Care Excellence. Asthma pathway (BTS, NICE, SIGN). Nov 2024 [internet publication].Full text
141. Hodkinson A, Bower P, Grigoroglou C, et al. Self-management interventions to reduce healthcare use and improve quality of life among patients with asthma: systematic review and network meta-analysis. BMJ. 2020 Aug 18;370:m2521.Full text Abstract
142. Ahmad S, Kew KM, Normansell R. Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids. Cochrane Database Syst Rev. 2015 Jun 19;(6):CD011306.Full text Abstract
143. Shang W, Wang G, Wang Y, et al. The safety of long-term use of inhaled corticosteroids in patients with asthma: a systematic review and meta-analysis. Clin Immunol. 2022 Mar;236:108960. Abstract
144. Oba Y, Anwer S, Patel T, et al. Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 Aug 21;8(8):CD013797.Full text Abstract
145. Crossingham I, Turner S, Ramakrishnan S, et al. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma. Cochrane Database Syst Rev. 2021 May 4;(5):CD013518.Full text Abstract
146. O'Byrne PM, FitzGerald JM, Bateman ED, et al. Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. Lancet Respir Med. 2021 Feb;9(2):149-58. Abstract
147. Nwaru BI, Ekström M, Hasvold P, et al. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020 Apr;55(4):1901872.Full text Abstract
148. Rogliani P, Beasley R, Cazzola M, et al. SMART for the treatment of asthma: a network meta-analysis of real-world evidence. Respir Med. 2021 Nov;188:106611.Full text Abstract
149. Rogliani P, Ritondo BL, Ora J, et al. SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. Eur Respir J. 2020 Sep;56(3):2000625.Full text Abstract
150. Janjua S, Schmidt S, Ferrer M, et al. Inhaled steroids with and without regular formoterol for asthma: serious adverse events. Cochrane Database Syst Rev. 2019 Sep 25;(9):CD006924.Full text Abstract
151. Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007 May 17;356(20):2040-52.Full text Abstract
152. Martinez FD, Chinchilli VM, Morgan WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet. 2011 Feb 19;377(9766):650-7. Abstract
153. Calhoun WJ, Ameredes BT, King TS, et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA. 2012 Sep 12;308(10):987-97.Full text Abstract
154. Sumino K, Bacharier LB, Taylor J, et al. A pragmatic trial of symptom-based inhaled corticosteroid use in African-American children with mild asthma. J Allergy Clin Immunol Pract. 2020 Jan;8(1):176-85.Full text Abstract
155. Hu Y, Kung J, Galatis D, et al. Short acting beta agonist use associated with increased mortality and morbidity in asthma patients: a systematic review and meta-analysis. J Pharm Pharm Sci. 2022;25:193-200.Full text Abstract
156. Stanford RH, Shah MB, D'Souza AO, et al. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012 Dec;109(6):403-7. Abstract
157. Bloom CI, Cabrera C, Arnetorp S, et al. Asthma-related health outcomes associated with short-acting β2-agonist inhaler use: an observational UK study as part of the SABINA global program. Adv Ther. 2020 Oct;37(10):4190-208.Full text Abstract
158. Amin S, Soliman M, McIvor A, et al. Usage patterns of short-acting β2-agonists and inhaled corticosteroids in asthma: a targeted literature review. J Allergy Clin Immunol Pract. 2020 Sep;8(8):2556-64. Abstract
159. Kaplan AG, Correia-de-Sousa J, McIvor A, et al. Global quality statements on reliever use in asthma in adults and children older than 5 years of age. Adv Ther. 2021 Mar;38(3):1382-96.Full text Abstract
160. Lugogo N, O'Connor M, George M, et al. Expert consensus on SABA use for asthma clinical decision-making: a delphi approach. Curr Allergy Asthma Rep. 2023 Nov;23(11):621-34.Full text Abstract
161. Bateman ED, Reddel HK, O'Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018 May 17;378(20):1877-87.Full text Abstract
162. Ni Chroinin M, Greenstone I, Lasserson TJ, et al. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD005307.Full text Abstract
163. Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD007313.Full text Abstract
164. Kew KM, Karner C, Mindus SM, et al. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013 Dec 16;(12):CD009019.Full text Abstract
165. Papi A, Corradi M, Pigeon-Francisco C, et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med. 2013 Mar;1(1):23-31. Abstract
166. Patel M, Pilcher J, Pritchard A, et al. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med. 2013 Mar;1(1):32-42. Abstract
167. Bateman ED, Harrison TW, Quirce S, et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res. 2011 Apr 4;12:38.Full text Abstract
168. Jorup C, Lythgoe D, Bisgaard H. Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma. Eur Respir J. 2018 Jan;51(1):1701688.Full text Abstract
169. Demoly P, Louis R, Søes-Petersen U, et al. Budesonide/formoterol maintenance and reliever therapy versus conventional best practice. Respir Med. 2009 Nov;103(11):1623-32.Full text Abstract
170. O'Shea O, Stovold E, Cates CJ. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2021 Apr 14;4:CD007694.Full text Abstract
171. Papi A, Chipps BE, Beasley R, et al. Albuterol-budesonide fixed-dose combination rescue inhaler for asthma. N Engl J Med. 2022 Jun 2;386(22):2071-83. Abstract
172. Beasley R, Harrison T, Peterson S, et al. Evaluation of budesonide-formoterol for maintenance and reliever therapy among patients with poorly controlled asthma: a systematic review and meta-analysis. JAMA Netw Open. 2022 Mar 1;5(3):e220615.Full text Abstract
173. Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2012 May 16;(5):CD002314.Full text Abstract
174. O'Byrne PM, Naya IP, Kallen A, et al. Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2-agonists in achieving asthma control. Chest. 2008 Dec;134(6):1192-9.Full text Abstract
175. Chalitsios CV, Shaw DE, McKeever TM. Corticosteroids and bone health in people with asthma: a systematic review and meta-analysis. Respir Med. 2021 May;181:106374.Full text Abstract
176. Sobieraj DM, Baker WL, Nguyen E, et al. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: a systematic review and meta-analysis. JAMA. 2018 Apr 10;319(14):1473-84.Full text Abstract
177. Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016 Jan 21;(1):CD011721.Full text Abstract
178. Kim LHY, Saleh C, Whalen-Browne A, et al. Triple vs dual inhaler therapy and asthma outcomes in moderate to severe asthma: a systematic review and meta-analysis. JAMA. 2021 Jun 22;325(24):2466-79. Abstract
179. Rogliani P, Ritondo BL, Calzetta L. Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies. Eur Respir J. 2021 Sep 2;58(3):2004233.Full text Abstract
180. Agusti A, Fabbri L, Lahousse L, et al. Single inhaler triple therapy (SITT) in asthma: systematic review and practice implications. Allergy. 2022 Apr;77(4):1105-113.Full text Abstract
181. Oba Y, Anwer S, Maduke T, et al. Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2022 Dec 6;12(12):CD013799.Full text Abstract
182. Muiser S, Gosens R, van den Berge M, et al. Understanding the role of long-acting muscarinic antagonists in asthma treatment. Ann Allergy Asthma Immunol. 2022 Apr;128(4):352-60.Full text Abstract
183. Menzies-Gow A, Moore WC, Wechsler ME. Difficult-to-control asthma management in adults. J Allergy Clin Immunol Pract. 2022 Feb;10(2):378-84. Abstract
184. Volmer T, Effenberger T, Trautner C, et al. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018 Oct;52(4):1800703.Full text Abstract
185. Cataldo D, Louis R, Michils A, et al. Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways. J Asthma. 2021 Apr;58(4):448-58.Full text Abstract
186. Hiles SA, McDonald VM, Guilhermino M, et al. Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis. Eur Respir J. 2019 Nov;54(5):1901381.Full text Abstract
187. Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017 Aug 12;390(10095):659-68. Abstract
188. Thomas D, McDonald VM, Stevens S, et al. Effect of azithromycin on asthma remission in adults with persistent uncontrolled asthma: a secondary analysis of a randomized, double-anonymized, placebo-controlled trial. Chest. 2024 Aug;166(2):262-70.Full text Abstract
189. Undela K, Goldsmith L, Kew KM, et al. Macrolides versus placebo for chronic asthma. Cochrane Database Syst Rev. 2021 Nov 22;11:CD002997.Full text Abstract
190. Zaroff JG, Cheetham TC, Palmetto N, et al. Association of azithromycin use with cardiovascular mortality. JAMA Netw Open. 2020 Jun 1;3(6):e208199.Full text Abstract
191. Bourdin A, Husereau D, Molinari N, et al. Matching-adjusted comparison of oral corticosteroid reduction in asthma: systematic review of biologics. Clin Exp Allergy. 2020 Apr;50(4):442-52.Full text Abstract
192. Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 May;75(5):1023-42.Full text Abstract
193. Calzetta L, Aiello M, Frizzelli A, et al. Oral corticosteroids dependence and biologic drugs in severe asthma: myths or facts? A systematic review of real-world evidence. Int J Mol Sci. 2021 Jul 1;22(13):7132.Full text Abstract
194. Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022 Jan 13;386(2):157-71.
195. Gallagher A, Edwards M, Nair P, et al. Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma. Cochrane Database Syst Rev. 2021 Oct 19;10:CD012929.Full text Abstract
196. Agache I, Rocha C, Beltran J, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: a systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 May;75(5):1043-57.Full text Abstract
197. Jackson K, Bahna SL. Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases. Expert Rev Clin Immunol. 2020 Mar;16(3):311-9.Full text Abstract
198. Tejwani V, Chang HY, Tran AP, et al. The asthma evidence base: a call for core outcomes in interventional trials. J Asthma. 2021 Jul;58(7):855-64.Full text Abstract
199. Edris A, Lahousse L. Monoclonal antibodies in type 2 asthma: an updated network meta-analysis. Minerva Med. 2021 Oct;112(5):573-81.Full text Abstract
200. Prætorius K, Henriksen DP, Schmid JM, et al. Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma. ERJ Open Res. 2021 Aug 31;7(3):00306-2021.Full text Abstract
201. Saco T, Ugalde IC, Cardet JC, et al. Strategies for choosing a biologic for your patient with allergy or asthma. Ann Allergy Asthma Immunol. 2021 Dec;127(6):627-37.Full text Abstract
202. Charles D, Shanley J, Temple SN, et al. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis. Clin Exp Allergy. 2022 May;52(5):616-27.Full text Abstract
203. Akenroye A, Lassiter G, Jackson JW, et al. Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis. J Allergy Clin Immunol. 2022 Nov;150(5):1097-105.e12.Full text Abstract
204. MacDonald KM, Kavati A, Ortiz B, et al. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Rev Clin Immunol. 2019 May;15(5):553-69.Full text Abstract
205. Faulkner KM, MacDonald K, Abraham I, et al. 'Real-world' effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis. Expert Rev Clin Immunol. 2021 Jan;17(1):73-83. Abstract
206. Colombo GL, Di Matteo S, Martinotti C, et al. Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review. Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619841350.Full text Abstract
207. Bousquet J, Humbert M, Gibson PG, et al. Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. J Allergy Clin Immunol Pract. 2021 Jul;9(7):2702-14.Full text Abstract
208. Li Y, Li X, Zhang B, et al. Predictive biomarkers for response to omalizumab in patients with severe allergic asthma: a meta-analysis. Expert Rev Respir Med. 2022 Sep;16(9):1023-33. Abstract
209. Humbert M, Taillé C, Mala L, et al. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018 May 10;51(5):1702523.Full text Abstract
210. Busse WW. Are peripheral blood eosinophil counts a guideline for omalizumab treatment? STELLAIR says no!. Eur Respir J. 2018 May 10;51(5):1800730.Full text
211. Just J, Thonnelier C, Bourgoin-Heck M, et al. Omalizumab effectiveness in severe allergic asthma with multiple allergic comorbidities: a post-hoc analysis of the STELLAIR Study. J Asthma Allergy. 2021;14:1129-38.Full text Abstract
212. Farne HA, Wilson A, Milan S, et al. Anti-IL-5 therapies for asthma. Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD010834.Full text Abstract
213. Ortega H, Menzies-Gow A, Llanos JP, et al. Rapid and consistent improvements in morning PEF in patients with severe eosinophilic asthma treated with mepolizumab. Adv Ther. 2018 Jul;35(7):1059-68.Full text Abstract
214. Israel E, Canonica GW, Brusselle G, et al. Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review. J Asthma. 2022 Nov;59(11):2201-17.Full text Abstract
215. Albers FC, Bratton DJ, Gunsoy NB, et al. Mepolizumab improves work productivity, activity limitation, symptoms, and rescue medication use in severe eosinophilic asthma. Clin Respir J. 2022 Mar;16(3):252-8.Full text Abstract
216. Albers FC, Papi A, Taillé C, et al. Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA. Respir Res. 2019 Jul 30;20(1):169.Full text Abstract
217. Lugogo N, Liu MC, Pavord I, et al. Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: a meta-analysis. J Allergy Clin Immunol Pract. 2021 Sep;9(9):3506-9.e3.Full text Abstract
218. Gerday S, Graff S, Moermans C, et al. Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline. Thorax. 2023 Nov;78(11):1138-41.Full text Abstract
219. Yan K, Balijepalli C, Sharma R, et al. Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysis. Immunotherapy. 2019 Dec;11(17):1491-505. Abstract
220. Bleecker ER, FitzGerald JM, Chanez P, et al; SIROCCO Study Investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta-2 agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):2115-27. Abstract
221. FitzGerald JM, Bleecker ER, Nair P, et al; CALIMA Study Investigators. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):2128-41. Abstract
222. Nair P, Wenzel S, Rabe KF, et al; ZONDA Trial Investigators. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017 Jun 22;376(25):2448-58.Full text Abstract
223. Harrison TW, Chanez P, Menzella F, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med. 2021 Mar;9(3):260-74. Abstract
224. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018 Jun 28;378(26):2486-96.Full text Abstract
225. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66.Full text Abstract
226. Agache I, Song Y, Rocha C, et al. Efficacy and safety of treatment with dupilumab for severe asthma: a systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma. Allergy. 2020 May;75(5):1058-68.Full text Abstract
227. Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022 Jan;10(1):11-25. Abstract
228. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017 Sep 7;377(10):936-46.Full text Abstract
229. Chan R, Stewart K, Misirovs R, et al. Targeting downstream type 2 cytokines or upstream epithelial alarmins for severe asthma. J Allergy Clin Immunol Pract. 2022 Feb 5 [Epub ahead of print].Full text Abstract
230. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021 May 13;384(19):1800-9. Abstract
231. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023 Jul 1;208(1):13-24.Full text Abstract
232. Wechsler ME, Menzies-Gow A, Brightling CE, et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respir Med. 2022 Jul;10(7):650-60. Abstract
233. Menzies-Gow A, Wechsler ME, Brightling CE, et al. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Lancet Respir Med. 2023 May;11(5):425-38. Abstract
234. Ando K, Fukuda Y, Tanaka A, et al. Comparative efficacy and safety of tezepelumab and other biologics in patients with inadequately controlled asthma according to thresholds of type 2 inflammatory biomarkers: a systematic review and network meta-analysis. Cells. 2022 Feb 26;11(5):819.Full text Abstract
235. Shaban Abdelgalil M, Ahmed Elrashedy A, Awad AK, et al. Safety and efficacy of tezepelumab vs. placebo in adult patients with severe uncontrolled asthma: a systematic review and meta-analysis. Sci Rep. 2022 Dec 3;12(1):20905.Full text Abstract
236. Feist J, Lipari M, Kale-Pradhan P. Tezepelumab in the treatment of uncontrolled severe asthma. Ann Pharmacother. 2023 Jan;57(1):62-70. Abstract
237. Menzies-Gow A, Steenkamp J, Singh S, et al. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. J Med Econ. 2022 Jan-Dec;25(1):679-90.Full text Abstract
238. Bourdin A, Brusselle G, Couillard S, et al. Phenotyping of severe asthma in the era of broad-acting anti-asthma biologics. J Allergy Clin Immunol Pract. 2024 Apr;12(4):809-23.Full text Abstract
239. Mansur AH, Gonem S, Brown T, et al. Biologic therapy practices in severe asthma; outcomes from the UK severe asthma Registry and survey of specialist opinion. Clin Exp Allergy. 2022 Sep 3.Full text Abstract
240. Asthma and Lung UK. Biologic therapies for severe asthma. May 2025 [internet publication].Full text
241. Menzies-Gow A, Gurnell M, Heaney LG, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2022 Jan;10(1):47-58.Full text Abstract
242. Jackson DJ, Heaney LG, Humbert M, et al. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Lancet. 2024 Jan 20;403(10423):271-81.Full text Abstract
243. Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol. 2014 Mar;133(3):921-3. Abstract
244. Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017 Jul;140(1):162-9.e2. Abstract
245. Moore WC, Kornmann O, Humbert M, et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). Eur Respir J. 2022 Jan;59(1):2100396. Abstract
246. Korn S, Bourdin A, Chupp G, et al. Integrated safety and efficacy among patients receiving benralizumab for up to 5 years. J Allergy Clin Immunol Pract. 2021 Dec;9(12):4381-92.e4. Abstract
247. Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019 May;143(5):1742-51.e7. Abstract
248. Busby J, Khoo E, Pfeffer PE, et al. The effects of oral corticosteroids on lung function, type-2 biomarkers and patient-reported outcomes in stable asthma: a systematic review and meta-analysis. Respir Med. 2020 Nov;173:106156. Abstract
249. Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010 Jan 15;181(2):116-24.Full text Abstract
250. Wahidi MM, Kraft M. Bronchial thermoplasty for severe asthma. Am J Respir Crit Care Med. 2012 Apr 1;185(7):709-14.Full text Abstract
251. Torrego A, Solà I, Munoz AM, et al. Bronchial thermoplasty for moderate or severe persistent asthma in adults. Cochrane Database Syst Rev. 2014 Mar 3;(3):CD009910.Full text Abstract
252. Chaudhuri R, Rubin A, Sumino K, et al. Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials. Lancet Respir Med. 2021 May;9(5):457-66. Abstract
253. O'Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018 May 17;378(20):1865-76.Full text Abstract
254. Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019 May 23;380(21):2020-30.Full text Abstract
255. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011 Sep 22;365(12):1088-98.Full text Abstract
256. Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015 Aug;70(8):748-56.Full text Abstract
257. Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016 Oct;4(10):781-96. Abstract
258. Korenblat P, Sher E, Berman G, et al. P069 effect of lebrikizumab on lung function in patients with severe eosinophilic asthma. Ann Allergy Asthma Immunol. 2021 Nov 1;127(5):S34.Full text
259. Corren J, Szefler SJ, Sher E, et al. Lebrikizumab in uncontrolled asthma: reanalysis in a well-defined type 2 population. J Allergy Clin Immunol Pract. 2024 May;12(5):1215-24.e3.Full text Abstract
260. Szefler SJ, Roberts G, Rubin AS, et al. Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS). Clin Transl Allergy. 2022 Jul;12(7):e12176.Full text Abstract
261. Kosloski MP, Kalliolias GD, Xu CR, et al. Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials. Clin Transl Sci. 2022 Feb;15(2):384-95.Full text Abstract
262. Xu C, Xin K, Kosloski MP, et al. Pharmacokinetics of subcutaneous itepekimab injection with an autoinjector device and prefilled syringe in healthy participants. Clin Pharmacol Drug Dev. 2024 Nov;13(11):1181-8.Full text Abstract
263. Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N Engl J Med. 2021 Oct 28;385(18):1656-68.Full text Abstract
264. Rabe KF, Celli BR, Wechsler ME, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021 Nov;9(11):1288-98. Abstract
265. Jackson DJ, Wechsler ME, Jackson DJ, et al. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. N Engl J Med. 2024 Dec 19;391(24):2337-49. Abstract
266. Davidescu L, Ursol G, Korzh O, et al. Efficacy and safety of masitinib in corticosteroid-dependent severe asthma: a randomized placebo-controlled trial. J Asthma Allergy. 2022;15:737-47.Full text Abstract
267. Park C, Jang JH, Kim C, et al. Real-world effectiveness of statin therapy in adult asthma. J Allergy Clin Immunol Pract. 2024 Feb;12(2):399-408.e6. Abstract
268. Naing C, Ni H. Statins for asthma. Cochrane Database Syst Rev. 2020 Jul 15;7(7):CD013268.Full text Abstract
269. Sunata K, Kabata H, Kuno T, et al. The effect of statins for asthma. A systematic review and meta-analysis. J Asthma. 2022 Apr;59(4):801-10. Abstract
270. Alabed M, Elemam NM, Ramakrishnan RK, et al. Therapeutic effect of statins on airway remodeling during asthma. Expert Rev Respir Med. 2022 Jan;16(1):17-24.Full text Abstract
271. Zhang QX, Zhang HF, Lu XT, et al. Statins improve asthma symptoms by suppressing inflammation: a meta-analysis based on RCTs. Eur Rev Med Pharmacol Sci. 2022 Nov;26(22):8401-10.Full text Abstract
272. Althoff MD, Gaietto K, Holguin F, et al. Obesity-related asthma: a pathobiology-based overview of existing and emerging treatment approaches. Am J Respir Crit Care Med. 2024 Nov 15;210(10):1186-200.Full text Abstract
273. Lee B, Man KKC, Wong E, et al. Antidiabetic medication and asthma attacks. JAMA Intern Med. 2025 Jan 1;185(1):16-25. Abstract
274. Rao R, Mei J, Chen H, et al. Association of metformin use with asthma development and adverse outcomes: a systematic review and meta-analysis. Medicine (Baltimore). 2024 Oct 4;103(40):e39785.Full text Abstract
275. Rogliani P, Calzetta L, Capuani B, et al. Glucagon-like peptide 1 receptor: a novel pharmacological target for treating human bronchial hyperresponsiveness. Am J Respir Cell Mol Biol. 2016 Dec;55(6):804-14.Full text Abstract
276. Foer D, Beeler PE, Cui J, et al. Asthma exacerbations in patients with type 2 diabetes and asthma on glucagon-like peptide-1 receptor agonists. Am J Respir Crit Care Med. 2021 Apr 1;203(7):831-40.Full text Abstract
277. Viby NE, Isidor MS, Buggeskov KB, et al. Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology. 2013 Dec;154(12):4503-11. Abstract
278. Bloodworth MH, Rusznak M, Pfister CC, et al. Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology. J Allergy Clin Immunol. 2018 Aug;142(2):683-7.e12.Full text Abstract
279. Toki S, Goleniewska K, Reiss S, et al. Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo. J Allergy Clin Immunol. 2018 Nov;142(5):1515-28.e8.Full text Abstract
280. Gurgel RK, Baroody FM, Damask CC, et al. Clinical practice guideline: immunotherapy for inhalant allergy. Otolaryngol Head Neck Surg. 2024 Mar;170(suppl 1):S1-42. Abstract
281. Toward Optimized Practice (Alberta Doctors). Chronic asthma. April 2018 [internet publication].Full text
282. Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020 Jan 2;55(1):1900588.Full text Abstract
283. Agache I, Lau S, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: house dust mite-driven allergic asthma. Allergy. 2019 May;74(5):855-73.Full text Abstract
284. Smith D, Du Rand I, Addy CL, et al. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. Thorax. 2020 May;75(5):370-404.Full text Abstract
285. Tupper OD, Andersen ZJ, Ulrik CS. Demographic, lifestyle and comorbid risk factors for all-cause mortality in a Danish cohort of middle-aged adults with incident asthma. BMJ Open. 2021 Oct 4;11(10):e049243.Full text Abstract
286. Lommatzsch M, Buhl R, Canonica GW, et al. Pioneering a paradigm shift in asthma management: remission as a treatment goal. Lancet Respir Med. 2024 Feb;12(2):96-9. Abstract
287. Shackleford A, Heaney LG, Redmond C, et al. Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis. Lancet Respir Med. 2025 Jan;13(1):23-34.Full text Abstract
288. Blaiss M, Oppenheimer J, Corbett M, et al. Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment. Ann Allergy Asthma Immunol. 2023 Dec;131(6):782-5. Abstract
289. Slade DJ, Kraft M. Airway remodeling from bench to bedside: current perspectives. Clin Chest Med. 2006 Mar;27(1):71-85. Abstract
290. Mascia K, Haselkorn T, Deniz YM, et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2005 Nov;116(5):970-5. Abstract
291. Chalitsios CV, Shaw DE, McKeever TM. Risk of osteoporosis and fragility fractures in asthma due to oral and inhaled corticosteroids: two population-based nested case-control studies. Thorax. 2021 Jan;76(1):21-8.Full text Abstract
292. Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193-204. Abstract
293. Prete A, Bancos I. Glucocorticoid induced adrenal insufficiency. BMJ. 2021 Jul 12;374:n1380. Abstract
294. Heatley H, Tran TN, Bourdin A, et al. Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma. Thorax. 2023 Sep;78(9):860-7.Full text Abstract
295. Dhippayom T, Wateemongkollert A, Mueangfa K, et al. Comparative efficacy of strategies to support self-management in patients with asthma: a systematic review and network meta-analysis. J Allergy Clin Immunol Pract. 2022 Mar;10(3):803-14. Abstract
296. Alexandre-Sousa P, Sousa N, Bento J, et al. Nurses' role in the control and treatment of asthma in adults: a systematic literature Rreview. Adv Respir Med. 2024 Apr 25;92(3):175-89.Full text Abstract
297. Nelsen LM, Kosinski M, Rizio AA, et al. A structured review evaluating content validity of the Asthma Control Test, and its consistency with U.S. guidelines and patient expectations for asthma control. J Asthma. 2022 Mar;59(3):628-37. Abstract
298. Chu F, Kappel N, Akel M, et al. Validity of the childhood asthma control test in diverse populations: a systematic review. Pediatr Pulmonol. 2023 May;58(5):1322-36. Abstract
299. Bansal A, Franklin L, Twohig H. Optimising inhaled therapy for patients with asthma. BMJ. 2024 Sep 20;386:e080353.
300. Kang HQ, Pen Y, He Y, et al. The experience of shared decision-making for people with asthma: a systematic review and metasynthesis of qualitative studies. Health Expect. 2024 Apr;27(2):e14039.Full text Abstract
301. Kew KM, Malik P, Aniruddhan K, et al. Shared decision-making for people with asthma. Cochrane Database Syst Rev. 2017 Oct 3;10(10):CD012330.Full text Abstract
302. Gatheral TL, Rushton A, Evans DJ, et al. Personalised asthma action plans for adults with asthma. Cochrane Database Syst Rev. 2017 Apr 10;4(4):CD011859.Full text Abstract
303. Riley IL, Jackson B, Crabtree D, et al. A scoping review of international barriers to asthma medication adherence mapped to the theoretical domains framework. J Allergy Clin Immunol Pract. 2021 Jan;9(1):410-8.e4. Abstract
304. van de Hei SJ, Dierick BJH, Aarts JEP, et al. Personalized medication adherence management in asthma and chronic obstructive pulmonary disease: a review of effective interventions and development of a practical adherence toolkit. J Allergy Clin Immunol Pract. 2021 Nov;9(11):3979-94.Full text Abstract
305. Monteiro C, Maricoto T, Prazeres F, et al. Determining factors associated with inhaled therapy adherence on asthma and COPD: a systematic review and meta-analysis of the global literature. Respir Med. 2022 Jan;191:106724.Full text Abstract
306. Visser CD, Antonisse LLM, Alleda FM, et al. Self-management support with the respiratory adherence care enhancer instrument in asthma and chronic obstructive pulmonary disease: an implementation trial. Br J Clin Pharmacol. 2024 May;90(5):1344-56.Full text Abstract
307. Chan A, De Simoni A, Wileman V, et al. Digital interventions to improve adherence to maintenance medication in asthma. Cochrane Database Syst Rev. 2022 Jun 13;6(6):CD013030.Full text Abstract
308. Sunjaya AP, Ansari S, Jenkins CR. A systematic review on the effectiveness and impact of clinical decision support systems for breathlessness. NPJ Prim Care Respir Med. 2022 Aug 20;32(1):29.Full text Abstract
309. Chongmelaxme B, Chaiyakunapruk N, Dilokthornsakul P. Association between adherence and severe asthma exacerbation: a systematic review and meta-analysis. J Am Pharm Assoc (2003). 2020 Sep-Oct;60(5):669-85.e2. Abstract
310. Kinley E, Skene I, Steed E, et al. Delivery of supported self-management in remote asthma reviews: a systematic rapid realist review. Health Expect. 2022 Aug;25(4):1200-14.Full text Abstract
311. McTague K, Prizeman G, Shelly S, et al. Youths with asthma and their experiences of self-management education: a systematic review of qualitative evidence. J Adv Nurs. 2022 Dec;78(12):3987-4002.Full text Abstract
312. Hale EM, Greene G, Mulvey C, et al. Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trial. Lancet Respir Med. 2023 Jul;11(7):591-601. Abstract
313. Almutairi M, Marriott JF, Mansur A. Effect of monitoring adherence to regular inhaled corticosteroid (ICS) alone or in combination with a long-acting β2-agonist (LABA) using electronic methods on asthma outcomes: a narrative systematic review. BMJ Open. 2023 Aug 16;13(8):e074127.Full text Abstract
314. Chongmelaxme B, Lee S, Dhippayom T, et al. The effects of telemedicine on asthma control and patients' quality of life in adults: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2019 Jan;7(1):199-216. Abstract
315. Jeminiwa R, Hohmann L, Qian J, et al. Impact of eHealth on medication adherence among patients with asthma: a systematic review and meta-analysis. Respir Med. 2019 Mar;149:59-68.Full text Abstract
316. Unni E, Gabriel S, Ariely R. A review of the use and effectiveness of digital health technologies in patients with asthma. Ann Allergy Asthma Immunol. 2018 Dec;121(6):680-91.Full text Abstract
317. Song X, Hallensleben C, Zhang W, et al. Blended self-management interventions to reduce disease burden in patients with chronic obstructive pulmonary disease and asthma: systematic review and meta-analysis. J Med Internet Res. 2021 Mar 31;23(3):e24602.Full text Abstract
318. Murphy J, McSharry J, Hynes L, et al. Prevalence and predictors of adherence to inhaled corticosteroids in young adults (15-30 years) with asthma: a systematic review and meta-analysis. J Asthma. 2021 May;58(5):683-705. Abstract
319. Busby J, McDowell PJ, Pfeffer PE, et al. Ethnic variation in asthma phenotypic presentation and outcomes: a cross-sectional analysis of the UK Biobank. Thorax. 2024 Jan 18;79(2):186-90.Full text Abstract
320. Israel E, Cardet JC, Carroll JK, et al. Reliever-triggered inhaled glucocorticoid in black and Latinx adults with asthma. N Engl J Med. 2022 Apr 21;386(16):1505-18.Full text Abstract
321. Roche N, Aggarwal B, Boucot I, et al. The impact of inhaler technique on clinical outcomes in adolescents and adults with asthma: a systematic review. Respir Med. 2022 Oct;202:106949.Full text Abstract
322. Abdelrahman MA, Saeed H, Osama H, et al. Effect of verbal counselling on metred-dose inhaler proper use and lung function test amongst asthmatic patients: a meta-analysis. Int J Clin Pract. 2021 Jun;75(6):e14077. Abstract
323. Rodriguez-Garcia C, Barreiro E, Muñoz-Gall X, et al. Common errors in inhalation therapy: Impact and solutions. Clin Respir J. 2020 Nov;14(11):1001-10.Full text Abstract
324. Murphy AC, Carroll W, Gotsell M, et al. How do patients determine when their inhaler is empty? Insights from an analysis of returned inhalers and a patient survey. BMJ Open Respir Res. 2024 Dec 25;11(1):e002579.Full text Abstract
325. Jia X, Zhou S, Luo D, et al. Effect of pharmacist-led interventions on medication adherence and inhalation technique in adult patients with asthma or COPD: a systematic review and meta-analysis. J Clin Pharm Ther. 2020 Oct;45(5):904-17.Full text Abstract
326. Saleem SS, Khan A, Aman R, et al. Impact of pharmacist-led educational intervention on knowledge of self-management among asthmatic patients: a prospective cohort study. BMJ Open. 2022 Jun 15;12(6):e058861.Full text Abstract
327. Ten Have P, van Hal P, Wichers I, et al. Turning green: the impact of changing to more eco-friendly respiratory healthcare - a carbon and cost analysis of Dutch prescription data. BMJ Open. 2022 Jun 14;12(6):e055546. Abstract
328. Wilkinson AJK, Maslova E, Janson C, et al. Greenhouse gas emissions associated with suboptimal asthma care in the UK: the SABINA healthCARe-Based envirONmental cost of treatment (CARBON) study. Thorax. 2024 Feb 27;79(5):412-21.Full text Abstract
329. Woodcock A, Janson C, Rees J, et al. Effects of switching from a metered dose inhaler to a dry powder inhaler on climate emissions and asthma control: post-hoc analysis. Thorax. 2022 Dec;77(12):1187-92.Full text Abstract
330. Usmani OS, Bosnic-Anticevich S, Dekhuijzen R, et al. Real-world impact of nonclinical inhaler regimen switches on asthma or COPD: a systematic review. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2624-37.Full text Abstract
331. Landré B, Nadif R, Goldberg M, et al. Asthma is associated with frailty among community-dwelling adults: the GAZEL cohort. BMJ Open Respir Res. 2020 Feb;7(1):e000526.Full text Abstract
332. Skloot GS, Busse PJ, Braman SS, et al. An official American Thoracic Society workshop report: evaluation and management of asthma in the elderly. Ann Am Thorac Soc. 2016 Nov;13(11):2064-77.Full text Abstract
333. Lee C, Alexander E, Lee R, et al. Behavioral interventions for asthma self-management in South Asian populations: a systematic review. J Asthma. 2021 Jan;58(1):112-20. Abstract
334. Henneberger PK, Patel JR, de Groene GJ, et al. Workplace interventions for treatment of occupational asthma. Cochrane Database Syst Rev. 2019 Oct 8;10(10):CD006308.Full text Abstract
335. Healthcare Quality Improvement Partnership. Breathing well respiratory audit report (NRAP). Jul 2024 [internet publication].Full text
336. Cooper M, Park-Lee E, Ren C, et al. Notes from the field: E-cigarette use among middle and high school students - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Oct 7;71(40):1283-5.Full text
337. Barnes C, Turon H, McCrabb S, et al. Interventions to prevent or cease electronic cigarette use in children and adolescents. Cochrane Database Syst Rev. 2023 Nov 15;11(11):CD015511.Full text Abstract
338. Quirce S, Domínguez-Ortega J, Luna JA. Novel approaches in occupational asthma diagnosis and management. Curr Opin Pulm Med. 2021 Jan;27(1):9-14. Abstract
339. Leas BF, D'Anci KE, Apter AJ, et al. Effectiveness of indoor allergen reduction in asthma management: a systematic review. J Allergy Clin Immunol. 2018 May;141(5):1854-69.Full text Abstract
340. Vazquez-Ortiz M, Angier E, Blumchen K, et al. Understanding the challenges faced by adolescents and young adults with allergic conditions: a systematic review. Allergy. 2020 Aug;75(8):1850-80.Full text Abstract
341. Cooley C, Park Y, Ajilore O, et al. Impact of interventions targeting anxiety and depression in adults with asthma. J Asthma. 2022 Feb;59(2):273-87.Full text Abstract
342. Tran L, Sharrad K, Kopsaftis Z, et al. Pharmacological interventions for the treatment of psychological distress in patients with asthma: a systematic review and meta-analysis. J Asthma. 2021 Jun;58(6):759-69. Abstract
343. Nebati E. Do psychological interventions improve outcomes for asthma in children and young people? Clin Exp Allergy. 2024 May;54(5):311-3.Full text Abstract
344. Sharrad KJ, Sanwo O, Cuevas-Asturias S, et al. Psychological interventions for asthma in children and adolescents. Cochrane Database Syst Rev. 2024 Jan 11;1(1):CD013420.Full text Abstract
345. Ji Z, López-de-Andrés A, Jiménez-García R, et al. Mental health in patients with asthma: A population-based case-control study. Respir Med. 2022 Mar;193:106758.Full text Abstract
346. Zhang Y, Cheng J, Li Y, et al. Suicidality among patients with asthma: a systematic review and meta-analysis. J Affect Disord. 2019 Sep 1;256:594-603. Abstract
347. Tyson L, Hardeman W, Marquette M, et al. A systematic review of the characteristics of interventions that promote physical activity in adults with asthma. J Health Psychol. 2022 Oct;27(12):2777-96.Full text Abstract
348. Valkenborghs SR, Anderson SL, Scott HA, et al. Exercise training programs improve cardiorespiratory and functional fitness in adults with asthma: a systemic review and meta-analysis. J Cardiopulm Rehabil Prev. 2022 Nov 1;42(6):423-33. Abstract
349. Holland AE, Spathis A, Marsaa K, et al. European Respiratory Society clinical practice guideline on symptom management for adults with serious respiratory illness. Eur Respir J. 2024 Jun 28;63(6):2400335.Full text Abstract
350. Santino TA, Chaves GS, Freitas DA, et al. Breathing exercises for adults with asthma. Cochrane Database Syst Rev. 2020 Mar 25;(3):CD001277.Full text Abstract
351. Nyenhuis SM, Kahwash B, Cooke A, et al. Recommendations for physical activity in asthma: a work group report of the AAAAI Sports, Exercise, and Fitness Committee. J Allergy Clin Immunol Pract. 2022 Feb;10(2):433-43. Abstract
352. Kahwash BM, Gregory KL, Sharp LK, et al. Results from a national survey of asthma provider beliefs and practices regarding exercise and asthma: a work group report of the AAAAI Committee on Sports, Exercise, and Fitness. J Allergy Clin Immunol Pract. 2022 Jul;10(7):1778-83.Full text Abstract
353. Kuder MM, Clark M, Cooley C, et al. A systematic review of the effect of physical activity on asthma outcomes. J Allergy Clin Immunol Pract. 2021 Sep;9(9):3407-21.e8.Full text Abstract
354. McLoughlin RF, Clark VL, Urroz PD, et al. Increasing physical activity in severe asthma: a systematic review and meta-analysis. Eur Respir J. 2022 Dec;60(6):2200546. Abstract
355. Li X, Mao C, Pan Y. Effect of routine therapy assisted by physical exercise on pulmonary function in patients with asthma in stable stage: a systematic review and meta-analysis of randomized clinical trials. Comput Math Methods Med. 2022;2022:2350297.Full text Abstract
356. Man W, Chaplin E, Daynes E, et al. British Thoracic Society clinical statement on pulmonary rehabilitation. Thorax. 2023 Oct;78(suppl 4):s2-15.Full text
357. Garagorri-Gutiérrez D, Leirós-Rodríguez R. Effects of physiotherapy treatment in patients with bronchial asthma: a systematic review. Physiother Theory Pract. 2022 Apr;38(4):493-503.Full text Abstract
358. Osadnik CR, Gleeson C, McDonald VM, et al. Pulmonary rehabilitation versus usual care for adults with asthma. Cochrane Database Syst Rev. 2022 Aug 22;8(8):CD013485.Full text Abstract
359. Okoniewski W, Lu KD, Forno E. Weight loss for children and adults with obesity and asthma: a systematic review of randomized controlled trials. Ann Am Thorac Soc. 2019 May;16(5):613-25.Full text Abstract
360. Hossain N, Arhi C, Borg CM. Is bariatric surgery better than nonsurgical weight loss for improving asthma control? A Systematic Review. Obes Surg. 2021 Apr;31(4):1810-32. Abstract
361. Lazarinis N, Jørgensen L, Ekström T, et al. Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax. 2014 Feb;69(2):130-6.Full text Abstract
362. Centers for Disease Control and Prevention. Vaccines & Immunizations: adult immunization schedule by age (addendum updated July 2, 2025); recommendations for ages 19 years or older, United States, 2025. Jul 2025 [internet publication].Full text
363. Centers for Disease Control and Prevention. Vaccines & immunizations: child and adolescent immunization schedule by age (addendum updated July 2, 2025). Jul 2025 [internet publication].Full text Abstract
364. Fortescue R, Kew KM, Leung MST. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev. 2020 Sep 14;(9):CD011293.Full text Abstract
365. Kappen J, Diamant Z, Agache I, et al. Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: an EAACI position paper. Allergy. 2023 Nov;78(11):2835-50.Full text Abstract
366. Novakova P, Tiotiu A, Baiardini I, et al. Allergen immunotherapy in asthma: current evidence. J Asthma. 2021 Feb;58(2):223-30.Full text Abstract
Use of this content is subject to our disclaimer